CSL

ARS Pharmaceuticals Highlights neffy Regulatory Progress and Reports First Quarter 2024 Financial Results

Retrieved on: 
星期四, 五月 9, 2024
CSL Limited, FDA, Investment, NDA, Research, MAA, CHMP, ASX, Trial of the century, ARS, PDUFA, European Medicines Agency, Patient, Adrenaline, Anaphylaxis, CSL, EMA, Caregiver, Committee, Allergy, Upper respiratory tract infection, CRL, Clinical trial, SAN, Journal, G&A

SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today reported business updates and financial results for the first quarter of 2024.

Key Points: 
  • Assuming approval on or before the anticipated PDUFA date, ARS Pharma anticipates launching neffy in the U.S. in the second half of 2024.
  • Following local regulatory approval of neffy, ARS Pharma will be responsible for supplying finished product to CSL Seqirus at a transfer price paid to ARS Pharma.
  • G&A expenses decreased from 2023 to 2024 primarily due to a pause in pre-commercial launch activities related to neffy.
  • Net Loss: Net loss was $10.3 million for the quarter ended March 31, 2024, compared to $15.0 million for the quarter ended March 31, 2023.

Carlyle Secured Lending, Inc. Announces Financial Results For First Quarter Ended 2024, Declares Second Quarter 2024 Dividends of $0.47 Per Common Share

Retrieved on: 
星期二, 五月 7, 2024
Investment, NAV, CSL, EST

On May 2, 2024, the Board of Directors declared a base quarterly common dividend of $0.40 per share plus a supplemental common dividend of $0.07 per share.

Key Points: 
  • On May 2, 2024, the Board of Directors declared a base quarterly common dividend of $0.40 per share plus a supplemental common dividend of $0.07 per share.
  • The dividends are payable on July 17, 2024 to common stockholders of record on June 28, 2024.
  • The Company will host a conference call at 11:00 a.m. EST on Wednesday, May 8, 2024 to discuss these quarterly financial results.
  • CSL has elected to be regulated as a business development company under the Investment Company Act of 1940, as amended.

uniQure Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

Retrieved on: 
星期二, 五月 7, 2024
FDA, Phase, Safety, Food, Fabry disease, Research, Immunosuppression, Male, Hand, IRB, Conference, Information technology, RBC Capital Markets, Patient, ALS, Acquisition, CSL, POC, Clinical trial, Temporal lobe epilepsy, SOD1, Pharmaceutical industry

LEXINGTON, Mass. and AMSTERDAM, May 07, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2024 and highlighted recent progress across its business.

Key Points: 
  • ~ Clinical trial initiation for Fabry disease on track to begin in second quarter of 2024, followed by refractory mesial temporal lobe epilepsy and SOD1-ALS in third quarter of 2024 ~
    LEXINGTON, Mass.
  • and AMSTERDAM, May 07, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today reported its financial results for the first quarter of 2024 and highlighted recent progress across its business.
  • We have obtained IRB approvals for initial sites, which are poised for imminent activation, and have also identified prospective patients.
  • The Company expects cash, cash equivalents and investment securities will fund operations into the second quarter of 2027.

Arcturus Therapeutics Announces First Quarter 2024 Financial Update and Pipeline Progress

Retrieved on: 
星期三, 五月 8, 2024
Biotechnology, Infectious Diseases, COVID-19, Health, Pharmaceutical, Society, COVID, Investment, Meiji, ARCT, Ornithine transcarbamylase deficiency, Safety, SARS-CoV-2, Travel, European Commission, Research, OTC, Cystic fibrosis, Lyme disease, RNA, MAA, Inborn errors of metabolism, Trial of the century, Vaccine, CDMO, Omicron, SRR, GMT, SAD, Liver, CSL, EMA, JPMorgan Chase, SIMD, Civil service commission, Infection, Messenger, Arcturus Therapeutics, Therapy, European Medicines Agency, Pharmaceutical industry

“Arcturus continues to make encouraging progress in both our vaccine and therapeutics pipeline,” said Joseph Payne, President & CEO of Arcturus.

Key Points: 
  • “Arcturus continues to make encouraging progress in both our vaccine and therapeutics pipeline,” said Joseph Payne, President & CEO of Arcturus.
  • To support this effort, Arcturus along with CDMO partners are on track to deliver the initial 4 million commercial doses of Kostaive in Q3.
  • The Company will share a progress update on the Phase 2 study on July 1, 2024.
  • The expected cash runway extends at least three years based on the current pipeline and programs through the first quarter of fiscal year 2027.

Ligand Reports First Quarter 2024 Financial Results

Retrieved on: 
星期二, 五月 7, 2024
Biotechnology, Pharmaceutical, Health, Oncology, FDA, Element, Investment, European Commission, Research, Molluscum contagiosum, CHMP, Parent, Agenus, PDUFA, Fibrosis, GAAP, CMA, PROTECT, Fast track (FDA), Priority review, Economics, Colorectal cancer, Forecasting, Liver disease, CSL Vifor, Committee, Bristol Myers Squibb, Therapy, Merck, Telephone, Safety, CASI, ASX, Immunoglobulin A, MRK, Sale, AMGN, Vikings, Gilead Sciences, Jazz Pharmaceuticals, LGND, NASH, Patient, CSL, Caregiver, Growth, Pharmaceutical industry

Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today reported financial results for the three months ended March 31, 2024, and provided an operating forecast and business updates.
  • “We are pleased to report another quarter of strong financial results driven by the performance of our commercial royalty portfolio.
  • Amortization of intangibles was $8.2 million for the first quarter of 2024, compared with $8.5 million for the same period in 2023.
  • Research and development expense was $6.0 million for the first quarter of 2024, compared with $6.7 million for the same period in 2023.

Recently Published Real-World Evidence Study Shows Effectiveness of Cell-Based Quadrivalent Influenza Vaccine Over Three Seasons

Retrieved on: 
星期四, 五月 2, 2024
Outcomes research, RWE, Real, WHO, Influenza, World Health Organization, Influenza vaccine, ASX, CSL, Season, Vaccine

A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seasons in the United States.

Key Points: 
  • A real-world evidence (RWE) study recently published in Open Forum Infectious Diseases (OFID) examined three consecutive U.S. flu seasons in the United States.
  • "With data collected over three consecutive seasons, our study suggests higher vaccine effectiveness of cell-based quadrivalent influenza vaccines compared with standard egg-based influenza vaccines."
  • These data build on the growing evidence of real-world data that shows the benefits of our cell-based influenza vaccine," said Gregg Sylvester, Chief Health Officer and Head of Medical Affairs, CSL Seqirus.
  • "At CSL Seqirus, we're continually driving vaccine technology forward, in order to improve effectiveness and help keep communities healthy."

CRITICAL IOT CONNECTIVITY EXPERTS, CSL, ARE DELIGHTED TO ANNOUNCE THE APPOINTMENT OF GREVILLE COE AS CHIEF COMMERCIAL OFFICER

Retrieved on: 
星期四, 五月 2, 2024
Growth, Ecosystem, Security, Radius, Critical infrastructure, CSL, Internet of things, Life

Greville brings a wealth of commercial and sales expertise to CSL, having previously served as the Managing Director of the telematics division at Radius for seven years.

Key Points: 
  • Greville brings a wealth of commercial and sales expertise to CSL, having previously served as the Managing Director of the telematics division at Radius for seven years.
  • He was instrumental in propelling the business through strategic acquisitions and organic growth initiatives, expanding the company's footprint globally.
  • Greville commented: "CSL is a fast-growing business with a dynamic leadership team and thriving culture.
  • Ed Heale, CSL's CEO, commented: "Greville has a proven track record of scaling businesses and driving significant growth.

CRITICAL IOT CONNECTIVITY EXPERTS, CSL, ARE DELIGHTED TO ANNOUNCE THE APPOINTMENT OF GREVILLE COE AS CHIEF COMMERCIAL OFFICER

Retrieved on: 
星期四, 五月 2, 2024
Growth, Ecosystem, Security, Radius, Critical infrastructure, CSL, Internet of things, Life

Greville brings a wealth of commercial and sales expertise to CSL, having previously served as the Managing Director of the telematics division at Radius for seven years.

Key Points: 
  • Greville brings a wealth of commercial and sales expertise to CSL, having previously served as the Managing Director of the telematics division at Radius for seven years.
  • He was instrumental in propelling the business through strategic acquisitions and organic growth initiatives, expanding the company's footprint globally.
  • Greville commented: "CSL is a fast-growing business with a dynamic leadership team and thriving culture.
  • Ed Heale, CSL's CEO, commented: "Greville has a proven track record of scaling businesses and driving significant growth.

Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy

Retrieved on: 
星期三, 四月 24, 2024
Nephrology, Kidney disease, Kidney, Div, Proteinuria, European Commission, Kidney failure, CHMP, Irbesartan, Immunoglobulin A, European, EGFR, Patient, CSL Vifor, CSL, Committee, Civil service commission, RAAS, Teaching hospital, Head, Therapy, CMA, SAN, Pharmaceutical industry

SAN DIEGO, April 24, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that the European Commission has granted conditional marketing authorization (CMA) for FILSPARI (sparsentan) for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion ≥1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.

Key Points: 
  • The CMA is granted for all member states of the European Union, as well as in Iceland, Liechtenstein and Norway.
  • “The approval of this innovative treatment is based on data from the only head-to-head phase 3 clinical trial in IgAN.
  • CSL Vifor expects to launch FILSPARI in the first European markets in the second half of 2024.
  • In 2021, Travere Therapeutics granted CSL Vifor exclusive commercialization rights for FILSPARI in Europe, Australia and New Zealand.

Eureka Shipping Announces Construction of New Cutting-Edge Cement Carrier for Great Lakes Trade

Retrieved on: 
星期二, 四月 16, 2024
Great Lakes region, Safety, Canada Steamship Lines, Atlantic Ocean, DWT, Wind, HVO, Steel, Baltic Sea, Noise, CSL, SMT, Shipbuilding

Montreal, April 16, 2024 (GLOBE NEWSWIRE) -- Eureka Shipping, a leading provider of sustainable, high-efficiency cement carrier services jointly owned by SMT Shipping and The CSL Group, is pleased to announce the construction of a state-of-art mechanical/pneumatic cement ship destined for operation in the Great Lakes.

Key Points: 
  • Montreal, April 16, 2024 (GLOBE NEWSWIRE) -- Eureka Shipping, a leading provider of sustainable, high-efficiency cement carrier services jointly owned by SMT Shipping and The CSL Group, is pleased to announce the construction of a state-of-art mechanical/pneumatic cement ship destined for operation in the Great Lakes.
  • "Building a ship aligned with eco-friendly principles is a top priority for both Eureka Shipping and our customer,” said Kai Grotterud, Managing Director of Eureka Shipping.
  • "Our new cement carrier is expected to contribute significantly to decarbonization by drastically reducing the emissions per metric tonne of cargo carried.
  • Eureka Shipping Ltd. is a leading provider of logistical services within the specialized segment of pneumatic and mechanical cement carriers.